This article is more than 5 years old. Information may no longer be current.
Bernard De Bruyne, MD, PhD, offers investigator insight into FAME II
Click Here to Manage Email Alerts
BARCELONA, SPAIN — In this video, Bernard De Bruyne, MD, PhD, of the Cardiovascular Center Aalst, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium, outlines results from the FAME II trial, presented at the ESC Congress.
The trial assessed the use of fractional flow reserve-guided PCI with second-generation drug-eluting stents in addition to medical therapy compared with medical therapy alone in patients with stable CAD. De Bruyne, of the Cardiovascular Center Aalst, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium, noted that the primary composite endpoint of death, MI and unplanned hospitalization with urgent revascularization occurred nearly five times more frequently among patients in the medical therapy arm at 2 years. This difference, he noted, was primarily driven by unplanned hospitalizations with urgent revascularization.
He added that patients with hemodynamically significant lesions who underwent stenting had similar clinical outcomes to patients without ischemia and with FFR >0.8 who underwent medical therapy alone. De Bruyne concluded that the FAME II trial is the first to provide hard data that FFR-guided PCI using second-generation DES improves outcomes vs. medical therapy alone in stable patients.